Commonly reported side effects of citalopram include: drowsiness, ejaculatory disorder, nausea, insomnia, and diaphoresis. Other side effects include: suicidal tendencies, agitation, diarrhea, impotence, sinusitis, anxiety, confusion, exacerbation of depression, lack of concentration, tremor, vomiting, anorexia, and xerostomia. See below for a comprehensive list of adverse effects.
Applies to citalopram: oral solution, oral tablet
Oral route (Tablet; Solution)
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared with placebo in adults aged 65 or older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients.
Along with its needed effects, citalopram may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking citalopram:
Incidence not known
Some side effects of citalopram may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to citalopram: oral solution, oral tablet
The side effects observed with citalopram in clinical trials were generally reported as mild and transient, occurring most frequently in the first 1 to 2 weeks of therapy, and attenuating subsequently. The most commonly reported side effects were nausea, somnolence, dry mouth, increased sweating, tremor, diarrhea, and ejaculation disorder.
Potentially life-threatening serotonin syndrome has been reported with SSRIs and SNRIs as monotherapy, but particularly with concomitant use of other serotonergic drugs and drugs that impair the metabolism of serotonin.
Very common (10% or more): Headache (up to 26.9%), somnolence (up to 17.9%), dizziness (up to 10.3%)
Common (1% to 10%): Amnesia, extrapyramidal disorder, migraine, paresthesia, tremor,
Uncommon (0.1% to 1%): Abnormal gait, ataxia, cerebrovascular accident, convulsions, dystonia, hypoesthesia, involuntary muscle contractions, neuralgia, speech disorder, syncope, hyperkinesia, hypertonia, hypokinesia, dyskinesia, vertigo, transient ischemic attack
Rare (less than 0.1%): Abnormal coordination, dyskinesia, grand mal convulsion, hyperesthesia, stupor
Frequency not reported: Akathisia, movement disorder, serotonin syndrome
Postmarketing reports: Choreoathetosis, myoclonus, neuroleptic malignant syndrome, nystagmus
Very common (10% or more): Nausea (up to 21.4%), dry mouth (up to 20%)
Common (1% to 10%): Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, increased saliva, taste loss/perversion, vomiting
Uncommon (0.1% to 1%): Abnormal bleeding (predominantly of the mucous membranes), dysphagia, eructation, esophagitis, gastrointestinal bleeding, gastritis, gastroenteritis, gingivitis, hemorrhoids, stomatitis, teeth grinding
Rare (less than 0.1%): Colitis, diverticulitis, duodenal ulcer, gastric ulcer, gastroesophageal reflux, gingival bleeding, glossitis, rectal hemorrhage
Frequency not reported: Gastrointestinal hemorrhage
Postmarketing reports: Pancreatitis
Very common (10% or more): Insomnia (up to 18.8%)
Common (1% to 10%): Abnormal dreams, aggravated depression, agitation, anxiety, apathy, confusion, depression, impaired concentration, nervousness, suicide attempt, sleep disorder
Uncommon (0.1% to 1%): Aggressive reaction, delusion, depersonalization, drug dependence, emotional lability, euphoria, hallucination, mania, panic reaction, paranoid reaction, paroniria, psychosis, psychotic depression
Rare (less than 0.1%): Catatonic reaction, melancholia, suicide-related events
Frequency not reported: Bruxism, restlessness, panic attack, suicidal ideation/behavior
Postmarketing reports: Delirium, withdrawal syndrome
Very common (10% or more): Asthenia (up to 11.5%)
Common (1% to 10%): Fatigue, fever/pyrexia, tinnitus, asthenia
Rare (less than 0.1%): Facial edema, malaise, rigors
Postmarketing reports: Spontaneous abortion
Very common (10% or more): Increased sweating (up to 11.3%)
Common (1% to 10%): Rash, pruritus
Uncommon (0.1% to 1%): Abnormal bleeding of the skin, acne, alopecia, dermatitis, dry skin, eczema, flushing, photosensitivity reaction, psoriasis, purpura, skin discoloration, urticaria
Rare (less than 0.1%): Decreased sweating, cellulitis, hypertrichosis, keratitis, melanosis, pruritus ani
Frequency not reported: Angioedema, ecchymosis
Postmarketing reports: Epidermal necrolysis, erythema multiforme
Urinary retention and galactorrhea have been reported with other SSRIs.
The estimates of the incidence of untoward sexual experience and performance may underestimate their actual incidence, partly because patients and physicians may be reluctant to discuss this issue. In placebo-controlled clinical trials, ejaculation disorder (primarily ejaculation delay) was reported as a treatment-emergent side effect at an incidence of 6% and at least twice the incidence in placebo-treated male patients.
Common (1% to 10%): Abnormal orgasm/anorgasmia (female), amenorrhea, decreased libido, dysmenorrhea, ejaculation disorders/ejaculation delay, impotence, menstrual disorders, polyuria, ejaculation failure, micturition disorders
Uncommon (0.1% to 1%): Breast enlargement, breast pain, dysuria, galactorrhea, increased libido, menorrhagia, micturition frequency, nonpuerperal lactation, vaginal bleeding, vaginal hemorrhage, urinary incontinence, urinary retention
Rare (less than 0.1%): Hematuria, oliguria
Frequency not reported: Metrorrhagia, priapism
Common (1% to 10%): Coughing, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, yawning
Uncommon (0.1% to 1%): Bronchitis, dyspnea, epistaxis, pneumonia
Rare (less than 0.1%): Asthma, bronchospasm, hiccups, increased sputum, laryngitis, pneumonitis, pulmonary embolism
Common (1% to 10%): Chest pain, hypotension, palpitations, postural hypotension, tachycardia
Uncommon (0.1% to 1%): Angina pectoris, atrial fibrillation, bradycardia, cardiac failure, edema (extremities), extrasystoles, hematomas, hot flushes, hypertension, myocardial infarction, myocardial ischemia
Rare (less than 0.1%): Bundle branch block, cardiac arrest, phlebitis, QT prolongation, torsades de pointes
Frequency not reported: Ventricular arrhythmia, orthostatic hypotension
Postmarketing reports: Thrombosis
This drug has been associated with a dose-related QT-interval prolongation; there have been reports of QT-interval prolongation and ventricular arrhythmia, including torsade de pointes, particularly in females, patients with hypokalemia, or with pre-existing QT-interval prolongation, or other cardiac disease.
Epidemiological studies, primarily in patients aged 50 years or older, have shown an increased risk of bone fractures in patients receiving SSRIs or TCAs.
Common (1% to 10%): Arthralgia, back pain, myalgia
Uncommon (0.1% to 1%): Arthritis, leg cramps, muscle weakness, skeletal pain
Rare (less than 0.1%): Bursitis, osteoporosis
Postmarketing reports: Rhabdomyolysis
Common (1% to 10%): Anorexia, decreased/increased weight, decreased/increased appetite
Uncommon (0.1% to 1%): Abnormal glucose tolerance, thirst
Rare (less than 0.1%): Alcohol intolerance, dehydration, hypokalemia, hyponatremia, hypoglycemia, obesity
Common (1% to 10%): Abnormal accommodation
Uncommon (0.1% to 1%): Abnormal vision, conjunctivitis, dry eyes, eye pain, mydriasis
Rare (less than 0.1%): Abnormal lacrimation, cataract, diplopia, photophobia, ptosis
Frequency not reported: Visual disturbance, acute narrow angle glaucoma
Postmarketing reports: Angle-closure glaucoma
Common (1% to 10%): Increased alkaline phosphatase
Uncommon (0.1% to 1%): Increased ALT, GGT, and AST
Rare (less than 0.1%): Bilirubinemia, cholelithiasis, cholecystitis, hepatitis, jaundice
Frequency not reported: Abnormal liver function test
Postmarketing reports: Cholestatic hepatitis, hepatic necrosis
Common (1% to 10%): Influenza-like symptoms
Rare (less than 0.1%): Hay fever
Uncommon (0.1% to 1%): Anemia, leukopenia, leukocytosis, lymphadenopathy
Rare (less than 0.1%): Coagulation disorder, granulocytopenia, hemorrhage, hypochromic anemia, lymphocytosis, lymphopenia
Frequency not reported: Thrombocytopenia
Postmarketing reports: Decreased prothrombin, hemolytic anemia
Rare (less than 0.1%): Goiter, hypothyroidism
Frequency not reported: Inappropriate ADH secretion
Postmarketing reports: Prolactinemia
Rare (less than 0.1%): Pyelonephritis, renal calculus, renal pain
Postmarketing reports: Acute renal failure
Frequency not reported: Anaphylactic reaction, hypersensitivity not otherwise specified
Postmarketing reports: Allergic reaction
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Citalopram Hydrobromide (www.drugs.com/citalopram.html).